Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Cidara Therapeutics Inc

Healthcare US CDTX

NoneUSD
0.00(0%)

Last update at 2026-02-05T21:09:46.399964Z

Day Range

--
LowHigh

52 Week Range

10.0024.40
LowHigh

Fundamentals

  • Previous Close 221.38
  • Market Cap246.23M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-30.10700M
  • Revenue TTM53.87M
  • Revenue Per Share TTM11.88
  • Gross Profit TTM -11.23200M
  • Diluted EPS TTM-23.9

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -29.52700M -42.46700M -72.11100M -41.09200M -59.01600M
Minority interest - - - - -
Net income -29.79900M -43.90900M -72.37300M -40.08500M -59.01600M
Selling general administrative 18.49M 18.74M 15.90M 16.24M 14.14M
Selling and marketing expenses - - - - -
Gross profit 64.29M 49.57M 12.07M 20.91M -49.14200M
Reconciled depreciation 1.23M -1.23000M 0.29M 0.33M 0.52M
Ebit -30.94300M -41.02500M -71.84900M -41.72400M -67.65900M
Ebitda -29.71800M -42.25500M -71.62000M -42.13500M -67.13600M
Depreciation and amortization 1.23M -1.23000M 0.23M -0.41100M 0.52M
Non operating income net other 0.19M - -0.26200M 0.63M 4.27M
Operating income -29.71800M -42.25500M -71.84900M -41.72400M -63.28500M
Other operating expenses 94.01M 91.83M 83.92M 62.64M 63.28M
Interest expense 0.19M 0.21M -0.26200M 0.22M 0.63M
Tax provision 0.27M - - - -
Interest income - - - 0.63M -
Net interest income 0.19M -0.21200M -0.26200M 0.22M 0.63M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.27M 1.44M 0.26M -1.00700M 4.27M
Total revenue 64.29M 49.57M 12.07M 20.91M 0.00000M
Total operating expenses 94.01M 91.83M 83.92M 62.64M 63.28M
Cost of revenue - - - 46.40M 49.14M
Total other income expense net 0.19M -0.21200M -0.26200M 0.63M 3.64M
Discontinued operations - - - - -
Net income from continuing ops -29.79900M -42.46700M -72.11100M -41.09200M -59.01600M
Net income applicable to common shares -29.79900M -42.46700M -74.87300M -41.09200M -69.34500M
Preferred stock and other adjustments - - 2.76M - 10.33M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 68.53M 47.59M 75.33M 60.42M 68.98M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.73M 6.53M 6.66M 10.10M 5.55M
Total liab 76.74M 50.50M 53.75M 49.71M 31.14M
Total stockholder equity -8.21000M -2.90400M 21.57M 10.71M 37.84M
Deferred long term liab - - - - -
Other current liab 37.25M 12.59M 15.06M 12.17M 7.73M
Common stock 0.00900M 0.00700M 0.00700M 0.00400M 0.00300M
Capital stock 0.00900M 0.00700M 0.00700M 0.00400M 0.00300M
Retained earnings -441.43100M -406.96600M -377.16700M -334.70000M -259.82700M
Other liab - - 18.41M 11.14M 31.14M
Good will - - - - -
Other assets - - 1.08M 2.89M 1.10M
Cash 35.78M 32.73M 62.27M 35.91M 60.27M
Cash and equivalents - - - - -
Total current liabilities 67.42M 29.97M 34.02M 38.56M 30.20M
Current deferred revenue 25.09M 14.61M 13.92M 13.87M 9.80M
Net debt -30.90100M -31.41400M -57.21200M -27.95000M -48.54300M
Short term debt 1.30M 1.32M 3.74M 7.96M 10.78M
Short long term debt - - 2.59M 7.02M 9.96M
Short long term debt total 4.88M 1.32M 5.06M 7.96M 11.72M
Other stockholder equity 433.21M 404.06M 398.73M 345.41M 297.66M
Property plant equipment - 0.22M 2.54M 0.34M 0.43M
Total current assets 60.85M 45.09M 71.70M 57.19M 65.81M
Long term investments - - - - -
Net tangible assets - -2.90400M 21.57M 10.71M 37.84M
Short term investments - - - - -
Net receivables 16.25M 5.83M 5.36M 11.18M 5.55M
Long term debt - - - - -
Inventory 6.10M - -2.59300M - -5.54600M
Accounts payable 3.77M 1.45M 1.30M 4.57M 1.89M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -2.84200M
Additional paid in capital - - - - -
Common stock total equity - 0.00700M - 0.00400M 0.00300M
Preferred stock total equity - - - - -
Retained earnings total equity - -406.96600M - -334.70000M -259.80000M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.05M 1.07M 1.08M 2.02M 1.10M
Deferred long term asset charges - - - - -
Non current assets total 7.67M 2.50M 3.63M 3.23M 3.16M
Capital lease obligations 4.88M 1.32M 2.47M 0.94M 1.76M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.11800M -0.04100M -0.18600M -0.03500M 14.48M
Change to liabilities -2.16800M 6.23M 7.64M 0.46M 0.76M
Total cashflows from investing activities -0.11800M -0.04100M -0.18600M -0.03500M 14.30M
Net borrowings -2.59300M -4.44400M -2.96300M -2.96300M -2.96300M
Total cash from financing activities -0.95100M 44.60M 37.28M 14.27M 56.15M
Change to operating activities - 2.39M 2.73M -1.53200M -0.34000M
Net income -29.79900M -42.46700M -72.11100M -41.09200M -59.01600M
Change in cash -29.54200M 19.32M -17.31900M -14.29400M 13.75M
Begin period cash flow 62.27M 42.95M 60.27M 74.56M 60.81M
End period cash flow 32.73M 62.27M 42.95M 60.27M 74.56M
Total cash from operating activities -28.47300M -25.23200M -54.41100M -28.53200M -56.70500M
Issuance of capital stock 2.36M 49.03M 40.23M 14.30M 6.44M
Depreciation 1.23M -1.23000M 0.23M 0.38M 0.52M
Other cashflows from investing activities - - - - 14.48M
Dividends paid - - - - -
Change to inventory - 1.09M -6.59100M - -
Change to account receivables -0.47700M 5.82M -11.16500M -0.01000M 0.32M
Sale purchase of stock 1.64M - 11.05M 9.01M 6.64M
Other cashflows from financing activities -0.72000M 0.00600M 0.01M -9.03200M 49.71M
Change to netincome 3.53M 2.61M 4.11M 4.69M 1.93M
Capital expenditures 0.12M 0.04M 0.19M 0.04M 0.18M
Change receivables -0.47700M - -11.16500M - -
Cash flows other operating 0.29M - 16.83M 7.07M -0.95100M
Exchange rate changes - - - - -
Cash and cash equivalents changes -29.54200M - -17.31900M -14.29400M 13.75M
Change in working capital -3.43200M 14.44M 13.36M 7.49M -0.39900M
Stock based compensation 3.53M 4.01M 4.09M 5.07M 5.71M
Other non cash items 0.00100M 0.01M 0.02M 0.04M 0.09M
Free cash flow -28.59100M -25.27300M -54.59700M -28.56700M -56.88200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CDTX
Cidara Therapeutics Inc		 - -% - - 5.75 4.57 2.25 3.05 -1.6378
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Cidara Therapeutics Inc

6310 Nancy Ridge Drive, San Diego, CA, United States, 92121

Key Executives

Name Title Year Born
Dr. Jeffrey L. Stein Ph.D. Pres, CEO & Exec. Director 1955
Dr. Taylor Sandison Chief Medical Officer 1972
Dr. Les Tari Ph.D. Chief Scientific Officer NA
Dr. Kevin M. Forrest Ph.D. Founder and Chief Strategy Officer 1977
Dr. Preetam Shah M.B.A., Ph.D. CFO, Chief Bus. Officer & Principal Accounting Officer 1973
Mr. Shane M. Ward COO & Chief Legal Officer 1975
Ms. Allison Lewis CCP, SPHR VP of HR NA
Mr. James M. Balkovec Sr. VP of Research NA
Ms. Laura A. Navalta Sr. VP of Clinical Operations NA
Ms. Carol Waldo Sr. VP of Regulatory Affairs & Quality Assurance NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.